YS BIOPHARMA CO LTD (YS)
KYG9845F1090 - Common Stock
YS Biopharma Granted Phase I Clinical Trial License of Therapeutic Chronic Hepatitis B Virus Vaccine
/PRNewswire/ -- YS Biopharma Co., Ltd. (Nasdaq: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing,...
YS Biopharma to Report First Nine Months of Fiscal Year 2024 Financial Results on April 19, 2024
/PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing,...
YS Biopharma Announces Board Changes and Strategic Leadership Appointments in Chinese Subsidiaries
/PRNewswire/ -- YS Biopharma Co., Ltd. (Nasdaq: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing,...
YS Biopharma Announces Results of Extraordinary General Meeting held on February 22, 2024
/PRNewswire/ -- YS Biopharma Co., Ltd. (Nasdaq: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing,...
YS Biopharma Announces Results of Extraordinary General Meeting and Responds to False Statements about the Meeting
/PRNewswire/ -- YS Biopharma Co., Ltd. (Nasdaq: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing,...
Shareholders Led by Yi Zhang Announce Successful Results of Removal of Directors and Election of New Directors of YS Biopharma Co., Ltd.
/PRNewswire/ -- Yi Zhang and shareholders representing over 59.2% of the outstanding shares of YS Biopharma Co., Ltd. (the "Company" or "YS") (NASDAQ: YS) (the...
YS Biopharma Announces Appointment of New Directors
/PRNewswire/ -- YS Biopharma Co., Ltd. (Nasdaq: YS) ("YS Biopharma" or the "Company", and together with its subsidiaries, "YS Group"), a global...
YS Biopharma Responds to a Notice of Extraordinary General Meeting of Shareholders of YS Biopharma Co., Ltd.
/PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing,...
YS Biopharma announces $40M private placement (NASDAQ:YS)
YS Biopharma has announced a $40M private placement financing, strengthening their balance sheet and providing resources for core operations and growth.
YS Biopharma Announces US$40 Million Private Placement Financing
/PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma") along with its subsidiaries ("YS Group" or the "Company"), a global biopharmaceutical...
Shareholders of YS Biopharma Announce an Extraordinary General Meeting
/PRNewswire/ -- Shareholders of YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma"), a global biopharmaceutical company dedicated to discovering, developing,...
YS Stock Earnings: YS Biopharma Co Misses EPS, Misses Revenue for Q2 2024
YS stock results show that YS Biopharma Co missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.
YS Biopharma Announces Unaudited Financial Results for the First Half of Fiscal Year 2024
/PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma") along with its subsidiaries ("YS Group" or the "Company"), a global biopharmaceutical...
YS Biopharma Announces Changes to its Board Committees
/PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing,...
YS Biopharma Responds to Unauthorized Press Release Regarding Extraordinary General Meeting
/PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing,...
YS Biopharma Co., Ltd. to Hold Extraordinary General Meeting on December 28, 2023
/PRNewswire/ -- YS Biopharma Co., Ltd. ("YS Biopharma" or the "Company") (NASDAQ: YS), a global biopharmaceutical company, today announced that upon the...
3 Penny Stocks That Are Too Compelling to Ignore
Although the sector presents extraordinary risks, for those seeking extreme returns, these top penny stocks to buy could get it done.
Noble Capital Markets Initiates Coverage on YS Biopharma With Outperform Rating and US$5.25 Price Target
/PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing,...
YS Biopharma receives Nasdaq notice regarding minimum bid price requirement (NASDAQ:YS)
YS Biopharma Co receives Nasdaq notice on non-compliance with minimum bid price requirement.
YS Biopharma Announces Receipt of Nasdaq Notice
/PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing,...
YS Biopharma Announces First Subject Enrollment in Pivotal Phase 3 Clinical Trial of PIKA Rabies Vaccine
/PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing,...
YS Biopharma Granted Patent in the U.S. for Immunotherapy Targeting Chronic Hepatitis B Virus Infection
/PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing,...
YS Biopharma to Participate in Participate in Citi's 18th Annual Biopharma Conference
/PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing,...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
We're starting off the week with a breakdown of the biggest pre-market stock movers worth reading about on Monday morning!